Opus Genetics (IRD) Other Non-Current Assets (2010 - 2020)
Opus Genetics (IRD) reported Other Non-Current Assets of $25681.0 for Q3 2020, little changed year-over-year from $25681.0 in Q4 2019, and little changed on a QoQ basis from $25681.0 in Q2 2020.
Opus Genetics (IRD) has 11 years of Other Non-Current Assets data on file, last reported at $25681.0 in Q3 2020.
- Quarterly Other Non-Current Assets changed 0.0% year-over-year to $25681.0 in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $25681.0 (changed 0.0% YoY) and the FY2019 annual result came in at $25681.0, down 16.58% from the prior year.
- Other Non-Current Assets was little changed at $25681.0 in Q3 2020 per IRD's latest filing, from $25681.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $30785.0 in Q1 2016 and bottomed at $25681.0 in Q2 2019.
- The 5-year median for Other Non-Current Assets is $30785.0 (2016), against an average of $29173.2.
- The widest annual swing landed in 2016, when Other Non-Current Assets increased 19.87%; it then decreased 16.58% in 2019.
- Tracing IRD's Other Non-Current Assets over 5 years: stood at $30785.0 in 2016, then changed by 0.0% to $30785.0 in 2017, then changed by 0.0% to $30785.0 in 2018, then dropped by 16.58% to $25681.0 in 2019, then changed by 0.0% to $25681.0 in 2020.
- Per Business Quant, the three latest IRD Other Non-Current Assets figures stand at $25681.0 (Q3 2020), $25681.0 (Q2 2020), and $25681.0 (Q1 2020).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 25,681.00 |
| Jun 30, 2020 | 25,681.00 |
| Mar 31, 2020 | 25,681.00 |
| Dec 31, 2019 | 25,681.00 |
| Sep 30, 2019 | 25,681.00 |
| Jun 30, 2019 | 25,681.00 |
| Mar 31, 2019 | 30,785.00 |
| Dec 31, 2018 | 30,785.00 |
| Sep 30, 2018 | 30,785.00 |
| Jun 30, 2018 | 30,785.00 |
| Mar 31, 2018 | 30,785.00 |
| Dec 31, 2017 | 30,785.00 |
| Sep 30, 2017 | 30,785.00 |
| Jun 30, 2017 | 30,785.00 |
| Mar 31, 2017 | 30,785.00 |
| Dec 31, 2016 | 30,785.00 |
| Sep 30, 2016 | 30,785.00 |
| Jun 30, 2016 | 30,785.00 |
| Mar 31, 2016 | 30,785.00 |
| Dec 31, 2015 | 30,785.00 |
| Sep 30, 2015 | 30,785.00 |
| Jun 30, 2015 | 30,785.00 |
| Mar 31, 2015 | 25,681.00 |
| Sep 30, 2014 | 37,500.00 |
| Jun 30, 2014 | 78,156.00 |
| Mar 31, 2014 | 163,530.00 |
| Dec 31, 2013 | 196,130.00 |
| Sep 30, 2013 | 509,179.00 |
| Jun 30, 2013 | 568,879.00 |
| Mar 31, 2013 | 957,180.00 |
| Dec 31, 2012 | 1.09 Mn |
| Sep 30, 2012 | 217,173.00 |
| Jun 30, 2012 | 726,391.00 |
| Mar 31, 2012 | 1.28 Mn |
| Dec 31, 2011 | 1.43 Mn |
| Sep 30, 2011 | 2.95 Mn |
| Jun 30, 2011 | 3.18 Mn |
| Dec 31, 2010 | 401,893.00 |